A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]")

Starting soon

Conditions studied: Human Papillomavirus-Related Malignant Neoplasm

In brief

This study evaluates the long term protection provided by either one or two doses of the HPV vaccine for patients who were part of the ESCUDDO study.

Key facts

Study ID

NCT07706673

Run by

National Cancer Institute (NCI)

People needed

9700

Starts

2026-08-03

Expected to finish

2031-01-15

Last updated by the study team

2026-07-28

Who can join

Age: 12 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• * Participation in ESCUDDO base study
• Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms
• A signed informed consent form for ESCUDDO LTFU.
• Opportunity to complete three total study visits

You may not qualify if…

• * Enrollment cannot occur beyond her 10 year study visit

Where it is running

• Agencia Costarricense de Investigaciones Biomédicas (ACIB) — Liberia, Guanacaste Province, Costa Rica

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.